Queen's researchers make killer superbug breakthrough
Researchers at Queen’s University Belfast together with the University of Vienna have discovered that treatment for the antibiotic resistant bacteria Klebsiella pneumoniae could lie within our bodies’ natural defences.
Multidrug resistance of microbes poses a serious global threat to human health. Globally, 700,000 people die every year due to antimicrobial resistance.
The bacterium Klebsiella pneumoniae causes a number of infections including sepsis, urinary tract infections and pneumonia. As Klebsiella becomes more resistant to antibiotics, these common infections are becoming increasingly difficult to treat, which has led to the World Health Organisation recently declaring an urgent need for new therapeutics to be discovered for Klebsiella.
Professor Jose Bengoechea from the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s University Belfast and one of the lead researchers explains: “Klebsiella pneumoniae is of particular concern as it can cause infections such as bladder infections and pneumonia and has mortality rates of 25-60%. Antibiotics that were previously used to treat these infections are no longer effective meaning treatment options for common illnesses are becoming increasingly limited.”
However, a recent discovery by researchers at Queen’s University and the University of Vienna could radically change the approach to treating this common infection. The research findings, published in the high profile journal PlosPathogens, show that interferons, naturally produced in our bodies, are fighting back against the bacterial Klebsiellainfection.
Professor Bengoechea explains: “Interferons are well known weapons found within our bodies that fight against infections caused by viruses. This pre-clinical study has found that interferons are being produced to fight against the infection caused by Klebsiella, which is fast becoming resistant to treatment by antibiotics.”
The research has discovered how immune cells arriving at the site of infection communicate and join forces to eradicate Klebsiella during lung infections. The study suggests that future therapies of severe Klebsiella infections could target the immune system, rather than the pathogen itself.
Professor Bengoechea added: “These findings indicate that we can focus on therapy that manipulates interferons to fight Klebsiella, maximising our bodies’ natural resources to treat disease and reducing the need to use antibiotics for these infections. Further investigations are needed but these are encouraging results and open new avenues of research to fight this killer infection. ”
This timely discovery coincides with the World Health Organization’s (WHO) ‘Antibiotic Awareness Week’ (13-19 November 2017), during which WHO are raising awareness of the dangers of the global threat of antibiotic resistance, to avoid a return to a time before the discovery of antibiotics when infectious diseases were the main cause of mortality.
The research study was led by Queen’s University Belfast in partnership with the University of Vienna as part of the EU INBIONET project, funded by BBSRC.
Notes to editors
Reference: Natural killer cell-intrinsic type I IFN signaling controls Klebsiella pneumoniae growth during lung infection, PlosPathogens, 7 November 2017.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.